We are live on ! Find out more
MNPR icon

Monopar Therapeutics
MNPR

7 hedge funds and large institutions have $132K invested in Monopar Therapeutics in 2020 Q1 according to their latest regulatory filings, with 5 funds opening new positions, increasing their positions, 2 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

150% more first-time investments, than exits

New positions opened: 5 | Existing positions closed: 2

75% more funds holding

Funds holding: 4 → 7 (+3)

0.02% less ownership

Funds ownership: 0.06% → 0.03% (-0.02%)

70% less capital invested

Capital invested by funds: $439K → $132K (-$307K)

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 2

Holders
7
Holders Change
+3
Holders Change %
+75%
% of All Funds
0.15%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
5
Increased
–
Reduced
2
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
+$144K
2
BlackRock
BlackRock
New York
+$35.1K
3
Victory Capital Management
Victory Capital Management
Texas
+$8.64K
4
TRCT
Tower Research Capital (TRC)
New York
+$877
5
SIAS
Shine Investment Advisory Services
Colorado
+$125

Top Sellers

Rank Fund Capital Flow
1
Bank of Montreal
Bank of Montreal
Ontario, Canada
-$216K
2
Morgan Stanley
Morgan Stanley
New York
-$93K
3
PCM
Prelude Capital Management
New York
-$25K
4
UBS Group
UBS Group
Switzerland
-$16K
Name Holding Trade Value Shares
Change 		Change in
Stake
Millennium Management
1
Millennium Management
New York
$85K +$144K +2,301 New
Morgan Stanley
2
Morgan Stanley
New York
$23K -$93K -1,486 -70%
BlackRock
3
BlackRock
New York
$20K +$35.1K +561 New
Victory Capital Management
4
Victory Capital Management
Texas
$4K +$8.64K +138 New
Bank of Montreal
5
Bank of Montreal
Ontario, Canada
– -$216K -2,600 Closed
PCM
6
Prelude Capital Management
New York
– -$25K -302 Closed
UBS Group
7
UBS Group
Switzerland
– -$16K -255 -99%
SIAS
8
Shine Investment Advisory Services
Colorado
– +$125 +2 New
TRCT
9
Tower Research Capital (TRC)
New York
– +$877 +14 New

MNPR Hedge Fund Activity: Q1 2020 in Review

7 of the 4,538 institutional investors tracked by Wall St. Rank reported a position in Monopar Therapeutics (MNPR) for Q1 2020, worth a combined $132K — down 70% from $439K a quarter earlier.

Buyers outnumbered sellers: 5 funds opened new MNPR positions and 2 closed out — a net gain of 3 holders — while 0 added to existing stakes and 2 trimmed.

The largest buyer was Millennium Management, opening a new position worth an estimated $144K. The largest seller was Bank of Montreal, exiting entirely with an estimated $216K sold.

  • 7 institutional investors held Monopar Therapeutics (MNPR) as of Q1 2020, up from 4 in Q4 2019.
  • Funds reported $132K of Monopar Therapeutics stock for Q1 2020, down 70% quarter-over-quarter.
  • 5 funds opened new Monopar Therapeutics positions in Q1 2020 and 2 closed out, a net change of +3 holders.
  • The largest Monopar Therapeutics buyer in Q1 2020 was Millennium Management, an estimated $144K added.
  • The largest Monopar Therapeutics seller in Q1 2020 was Bank of Montreal, an estimated $216K sold.

Based on aggregated 13F filings for Q1 2020.